ClinicalTrials.gg
CompletedNCT06190691Updated Jan 9, 2025Results posted

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

A Phase 1 interventional study of Pirtobrutinib in Healthy and Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 8 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Dec 2020, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.

Enrollment
3rd of 12
36 · median 34
Started
2020
the only one that year
Phase 1
12 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 12 in phase 1, and was the 9th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hepatic Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last about 46 days.

03

Conditions studied

  • Healthy
  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with mild, moderate or severe hepatic impairment and healthy participants with normal hepatic function
  • Males and females of non-.
  • Within (BMI) range 18.5 to 40.0 kilograms per square meter (kg/m²).
  • Participants will be in good health, based on medical history, physical examination findings, vital signs, 12 lead (ECG), and clinical laboratory tests, as determined by the Investigator (or designee).
  • Able to comply with all study procedures, including the 8-night stay at the Clinical Research Unit and follow-up phone call.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any of the following, deemed by the Investigator (or designee), and/or Sponsor:

    1. pancreatitis
    2. peptic ulcer disease
    3. intestinal malabsorption
    4. gastric reduction surgery
    5. history or presence of clinically significant cardiovascular disease.
  • Participants with out-of-range, at-rest vital signs.
  • Abnormal laboratory values determined to be clinically significant by the Investigator (or designee).
  • Clinically significant abnormality, as determined by the Investigator (or designee), from physical examination.
  • Participation in any other study drug trial involving administration of any investigational drug in the past 30 days or 5 half-lives, whichever was longer, prior to the first dose administration (Day 1).
  • Use or intention to use any prescription or over-the-counter medications within 14 days prior to the first dose administration (Day 1) and through end of trial.
  • History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide or comply with study instructions, or that might confound the interpretation of the study results, or put the participant at undue risk.
  • Donation of blood from 56 days prior to Screening, plasma or from 4 weeks prior to Screening.
  • Receipt of blood products within 2 months prior to Check-in (Day -1).
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, biliary, renal, hematological, pulmonary, cardiovascular (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal (GI), neurological, or psychiatric disorder (as determined by the Investigator).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Pirtobrutinib (Normal Hepatic Function)

    Participants received a single dose of Pirtobrutinib 200 milligrams (mg) administered orally on Day 1.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib (Mild Hepatic Impairment)

    Participants received a single dose of Pirtobrutinib 200 mg administered orally on Day 1.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib (Moderate Hepatic Impairment)

    Participants received a single dose of Pirtobrutinib 200 mg administered orally on Day 1.

    Drug: Pirtobrutinib

  • Experimental
    Pirtobrutinib (Severe Hepatic Impairment)

    Participants received a single dose of Pirtobrutinib 200 mg administered orally on Day 1.

    Drug: Pirtobrutinib

Interventions

  • Administered orally

    Also known as: LOXO-305, LY3527727

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib

    PK: Cmax of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  2. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

    PK: Tmax of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

    PK: AUC0-t of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  4. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib

    PK: AUC0-inf of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  5. PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

    PK: %AUCextrap of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  6. PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib

    PK: t½ of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  7. PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

    PK: CL/F of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  8. PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib

    PK: Vz/F of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  9. PK: Mean Residence Time (MRT) of Pirtobrutinib

    MRT is the average time a drug molecule stays in the body, calculated from the AUC0-inf.

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  10. PK: Unbound Cmax (Cmax,u) of Pirtobrutinib

    Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  11. PK: Unbound AUC0-t (AUC0-t,u) of Pirtobrutinib

    AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  12. PK: Unbound AUC0-inf (AUC0-inf,u) of Pirtobrutinib

    AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  13. PK: Unbound CL/F (CL/F,u) of Pirtobrutinib

    CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  14. PK: Unbound Vz/F (Vz/F,u) of Pirtobrutinib

    Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  15. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Normal Hepatic Function)

    PK: λZ of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  16. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Mild Hepatic Function)

    PK: λZ of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  17. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Moderate Hepatic Function)

    PK: λZ of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

  18. PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Severe Hepatic Function)

    PK: λZ of pirtobrutinib

    Time frame: Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)

07

Results

Posted Jan 9, 2025

Participant flow

Participant flow — Overall Study
MilestonePirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
Started14886
Received dose of pirtobrutinib14886
Completed12886
Not completed2000
Withdrew: Adverse event2000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib

PK: Cmax of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib
nanogram per milliliter (ng/mL)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Pirtobrutinib4240 ± 32.44410 ± 22.74140 ± 20.83270 ± 22.8
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

PK: Tmax of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Median · hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
hoursPirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib2.50 (1 to 8)2.25 (1 to 6)2.25 (1 to 3)2.78 (2 to 4)
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

PK: AUC0-t of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib96800 ± 21.289900 ± 4384600 ± 31.771500 ± 14.8
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib

PK: AUC0-inf of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Pirtobrutinib98000 ± 20.790900 ± 42.785700 ± 31.172200 ± 14.6
PrimaryPK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib

PK: %AUCextrap of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · percentage of AUCextrap
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib
percentage of AUCextrapPirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib0.978 ± 67.31.13 ± 34.41.14 ± 54.70.921 ± 50.4
PrimaryPK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib

PK: t½ of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · hours
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib
hoursPirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib21.2 ± 20.919.8 ± 27.718 ± 16.315.5 ± 26.6
PrimaryPK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib

PK: CL/F of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
liter per hour (L/h)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib2.04 ± 20.72.20 ± 42.72.33 ± 31.12.77 ± 14.6
PrimaryPK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib

PK: Vz/F of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · Liter (L)
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib
Liter (L)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Pirtobrutinib62.4 ± 29.562.9 ± 45.160.6 ± 30.161.8 ± 30.5
PrimaryPK: Mean Residence Time (MRT) of Pirtobrutinib

MRT is the average time a drug molecule stays in the body, calculated from the AUC0-inf.

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · hours
PK: Mean Residence Time (MRT) of Pirtobrutinib
hoursPirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Mean Residence Time (MRT) of Pirtobrutinib28.8 ± 17.627.7 ± 26.325 ± 1424 ± 26.2
PrimaryPK: Unbound Cmax (Cmax,u) of Pirtobrutinib

Cmax,u was calculated by multiplying Cmax by Fu (i.e., Cmax\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Unbound Cmax (Cmax,u) of Pirtobrutinib
nanogram per milliliter (ng/mL)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Unbound Cmax (Cmax,u) of Pirtobrutinib107 ± 31.2133 ± 16.3118 ± 26.5111 ± 27.5
PrimaryPK: Unbound AUC0-t (AUC0-t,u) of Pirtobrutinib

AUC0-t,u was calculated by multiplying AUC0-t by Fu (i.e., AUC0-t\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Unbound AUC0-t (AUC0-t,u) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Unbound AUC0-t (AUC0-t,u) of Pirtobrutinib2440 ± 22.82710 ± 32.32410 ± 39.62410 ± 28.5
PrimaryPK: Unbound AUC0-inf (AUC0-inf,u) of Pirtobrutinib

AUC0-inf,u was calculated by multiplying AUC0-inf by Fu (i.e., AUC0-inf\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
PK: Unbound AUC0-inf (AUC0-inf,u) of Pirtobrutinib
hour*nanogram per milliliter (h*ng/mL)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Unbound AUC0-inf (AUC0-inf,u) of Pirtobrutinib2470 ± 22.62740 ± 32.12440 ± 39.12440 ± 28.5
PrimaryPK: Unbound CL/F (CL/F,u) of Pirtobrutinib

CL/F,u was calculated by multiplying CL/F by Fu (i.e., CL/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · liter per hour (L/h)
PK: Unbound CL/F (CL/F,u) of Pirtobrutinib
liter per hour (L/h)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Unbound CL/F (CL/F,u) of Pirtobrutinib80.9 ± 22.673 ± 32.181.9 ± 39.182 ± 28.5
PrimaryPK: Unbound Vz/F (Vz/F,u) of Pirtobrutinib

Vz/F,u was calculated by multiplying Vz/F by Fu (i.e., Vz/F\*Fu). Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. It is expressed as a decimal and will be calculated from protein binding concentration data as the unbound drug concentration divided by the total drug concentration in plasma. The concentrations of total and unbound drug were determined in a sample of predose plasma fortified with a known concentration of drug.

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Geometric mean · Liter (L)
PK: Unbound Vz/F (Vz/F,u) of Pirtobrutinib
Liter (L)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
PK: Unbound Vz/F (Vz/F,u) of Pirtobrutinib2470 ± 262090 ± 342130 ± 33.11830 ± 36.3
PrimaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Normal Hepatic Function)

PK: λZ of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Normal Hepatic Function)
1/hour (1/h)Pirtobrutinib (Normal Hepatic Function)
Subject 10.0334
Subject 20.0323
Subject 30.0418
Subject 40.0287
Subject 50.0231
Subject 60.0319
Subject 70.0420
Subject 80.0262
Subject 90.0292
Subject 100.0291
Subject 110.0299
Subject 120.0308
Subject 130.0399
Subject 140.0491
PrimaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Mild Hepatic Function)

PK: λZ of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Mild Hepatic Function)
1/hour (1/h)Pirtobrutinib (Mild Hepatic Impairment)
Subject 150.0270
Subject 160.0448
Subject 170.0453
Subject 180.0336
Subject 190.0234
Subject 200.0273
Subject 210.0432
Subject 220.0440
PrimaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Moderate Hepatic Function)

PK: λZ of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Moderate Hepatic Function)
1/hour (1/h)Pirtobrutinib (Moderate Hepatic Impairment)
Subject 230.0377
Subject 240.0387
Subject 250.0364
Subject 260.0430
Subject 270.0395
Subject 280.0467
Subject 290.0419
Subject 300.0272
PrimaryPK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Severe Hepatic Function)

PK: λZ of pirtobrutinib

Time frame:
Day 1 (predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose)
Reported as:
Number · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib (Severe Hepatic Function)
1/hour (1/h)Pirtobrutinib (Severe Hepatic Impairment)
Subject 310.0401
Subject 320.0526
Subject 330.0279
Subject 340.0522
Subject 350.0465
Subject 360.0567

Adverse events

Collected over Baseline to Follow-up (Up To Day 17). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirtobrutinib (Normal Hepatic Function)0/14 (0%)0/14 (0%)3/14 (21.4%)
Pirtobrutinib (Mild Hepatic Impairment)0/8 (0%)0/8 (0%)2/8 (25%)
Pirtobrutinib (Moderate Hepatic Impairment)0/8 (0%)0/8 (0%)0/8 (0%)
Pirtobrutinib (Severe Hepatic Impairment)0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventPirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)
ConstipationGastrointestinal disorders0/141/80/81/6
SARS-CoV-2 test positiveInvestigations2/140/80/80/6
HeadacheNervous system disorders0/141/80/80/6
DiarrhoeaGastrointestinal disorders1/140/80/80/6

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)Total
Mean54.4 ± 8.2256.8 ± 4.56056.3 ± 3.92052.3 ± 9.35055 ± 6.880
Sex: Female, Male
Sex: Female, Male(Participants)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)Total
Female432110
Male1056526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)Total
Hispanic or Latino554519
Not Hispanic or Latino934117
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American32005
White1168631
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Pirtobrutinib (Normal Hepatic Function)Pirtobrutinib (Mild Hepatic Impairment)Pirtobrutinib (Moderate Hepatic Impairment)Pirtobrutinib (Severe Hepatic Impairment)Total
United States1488636
08

Study locations

8 sites
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Advanced Pharma Clinical Research
    Miami, Florida 33147, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • The Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Dec 2021, 12 months.

Results were first posted in Jan 2025, 3 years after primary completion.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 12 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Jan 5, 2024
StartActual
Dec 18, 2020
Primary completionActual
Dec 30, 2021
CompletionActual
Dec 30, 2021
Results first posted
Jan 9, 2025
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06190691
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Dec 18, 2020
Primary completion
Dec 30, 2021
Completion
Dec 30, 2021
Results posted
Jan 9, 2025
Last update
Jan 9, 2025

Study contacts

Renée Ward, MD, PhD
study director · Loxo Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion